COVESTRO AG (1COV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1COV - DE0006062144 - Common Stock
59.98 EUR
+0.18 (+0.3%)
Taking everything into account, 1COV scores 2 out of 10 in our fundamental rating. 1COV was compared to 75 industry peers in the Chemicals industry. 1COV may be in some trouble as it scores bad on both profitability and health. 1COV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
1COV had negative earnings in the past year.
1COV had a positive operating cash flow in the past year.
In multiple years 1COV reported negative net income over the last 5 years.
Each year in the past 5 years 1COV had a positive operating cash flow.
1.2 Ratios
The Return On Assets of 1COV (-3.46%) is worse than 76.00% of its industry peers.
The Return On Equity of 1COV (-7.52%) is worse than 77.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.46% | ||
| ROE | -7.52% | ||
| ROIC | N/A |
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of 1COV has declined.
With a Gross Margin value of 13.93%, 1COV is not doing good in the industry: 77.33% of the companies in the same industry are doing better.
1COV's Gross Margin has declined in the last couple of years.
1COV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.93% |
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
2. Health
2.1 Basic Checks
1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
1COV has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for 1COV has been increased compared to 5 years ago.
Compared to 1 year ago, 1COV has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.27 indicates that 1COV is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.27, 1COV perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
1COV has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
1COV has a Debt to Equity ratio of 0.34. This is comparable to the rest of the industry: 1COV outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.27 |
ROIC/WACCN/A
WACC6.37%
2.3 Liquidity
1COV has a Current Ratio of 1.36. This is a normal value and indicates that 1COV is financially healthy and should not expect problems in meeting its short term obligations.
1COV has a Current ratio of 1.36. This is in the lower half of the industry: 1COV underperforms 74.67% of its industry peers.
A Quick Ratio of 0.73 indicates that 1COV may have some problems paying its short term obligations.
The Quick ratio of 1COV (0.73) is worse than 76.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for 1COV have decreased strongly by -76.09% in the last year.
The Revenue has decreased by -5.27% in the past year.
The Revenue has been growing slightly by 2.70% on average over the past years.
EPS 1Y (TTM)-76.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.06%
Revenue 1Y (TTM)-5.27%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-11.99%
3.2 Future
1COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.37% yearly.
Based on estimates for the next years, 1COV will show a small growth in Revenue. The Revenue will grow by 1.10% on average per year.
EPS Next Y-32.24%
EPS Next 2Y53.57%
EPS Next 3Y43.92%
EPS Next 5Y20.37%
Revenue Next Year-7.37%
Revenue Next 2Y-2.5%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.1%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 1COV. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 117.84, the valuation of 1COV can be described as expensive.
Based on the Price/Forward Earnings ratio, 1COV is valued a bit more expensive than 73.33% of the companies in the same industry.
1COV's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 117.84 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1COV is valued a bit more expensive than 69.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17 |
4.3 Compensation for Growth
A more expensive valuation may be justified as 1COV's earnings are expected to grow with 43.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.57%
EPS Next 3Y43.92%
5. Dividend
5.1 Amount
1COV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:1COV (12/22/2025, 7:00:00 PM)
59.98
+0.18 (+0.3%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners23.42%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.34B
Revenue(TTM)13.40B
Net Income(TTM)-458.00M
Analysts49.47
Price Target62.53 (4.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.22%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.67%
Min EPS beat(2)-139.31%
Max EPS beat(2)-0.04%
EPS beat(4)0
Avg EPS beat(4)-380.46%
Min EPS beat(4)-1222.75%
Max EPS beat(4)-0.04%
EPS beat(8)1
Avg EPS beat(8)-4244%
EPS beat(12)2
Avg EPS beat(12)-2876.36%
EPS beat(16)3
Avg EPS beat(16)-2162.14%
Revenue beat(2)0
Avg Revenue beat(2)-4.63%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-2.34%
Revenue beat(4)0
Avg Revenue beat(4)-4.71%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)-2.34%
Revenue beat(8)0
Avg Revenue beat(8)-4.43%
Revenue beat(12)0
Avg Revenue beat(12)-4.49%
Revenue beat(16)3
Avg Revenue beat(16)-2.5%
PT rev (1m)0.26%
PT rev (3m)-0.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-62.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.71%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)-3.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 117.84 | ||
| P/S | 0.85 | ||
| P/FCF | N/A | ||
| P/OCF | 14.21 | ||
| P/B | 1.86 | ||
| P/tB | 2.29 | ||
| EV/EBITDA | 17 |
EPS(TTM)-2.43
EYN/A
EPS(NY)0.51
Fwd EY0.85%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)4.22
OCFY7.04%
SpS70.92
BVpS32.22
TBVpS26.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.46% | ||
| ROE | -7.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.93% | ||
| FCFM | N/A |
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score3
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 92.05% | ||
| Cap/Sales | 6.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 2.27 |
F-Score3
WACC6.37%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.06%
EPS Next Y-32.24%
EPS Next 2Y53.57%
EPS Next 3Y43.92%
EPS Next 5Y20.37%
Revenue 1Y (TTM)-5.27%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-11.99%
Revenue Next Year-7.37%
Revenue Next 2Y-2.5%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.1%
EBIT growth 1Y-220.31%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year238.79%
EBIT Next 3Y78.95%
EBIT Next 5Y42.34%
FCF growth 1Y-116.5%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y-45.3%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%
COVESTRO AG / 1COV.DE FAQ
What is the fundamental rating for 1COV stock?
ChartMill assigns a fundamental rating of 2 / 10 to 1COV.DE.
What is the valuation status of COVESTRO AG (1COV.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to COVESTRO AG (1COV.DE). This can be considered as Overvalued.
Can you provide the profitability details for COVESTRO AG?
COVESTRO AG (1COV.DE) has a profitability rating of 1 / 10.
How financially healthy is COVESTRO AG?
The financial health rating of COVESTRO AG (1COV.DE) is 3 / 10.